slightbourne@noblecapitalmarkets.com, Author at Channelchek

Eli Lilly Pays $3.8 Billion for AtaiBeckley as Big Pharma’s Push Into Mental Health Enters a New Phase

Posted on July 16, 2026July 16, 2026 by [email protected]

The pharmaceutical industry’s appetite for neuroscience innovation just produced one of the most significant mental health deals in years. Eli Lilly (NYSE: LLY) announced Wednesday it has entered into a definitive agreement to acquire AtaiBeckley (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing rapid-acting therapies for treatment-resistant depression and other serious mental health conditions. The deal values AtaiBeckley at approximately $2.8 billion in upfront equity consideration, with an additional $1.0 billion in potential milestone-based contingent value rights, bringing the total potential transaction value to approximately $3.8 billion.

AtaiBeckley shareholders will receive $6.75 per share in cash at closing, representing a 40% premium to the stock’s 30-day volume-weighted average trading price. The contingent value rights are tied to specific development and regulatory milestones across the company’s two most advanced programs. The transaction is expected to close in the third quarter of 2026.

What Lilly Is Acquiring

AtaiBeckley’s pipeline is built around a class of compounds called rapid-acting neuroplastogens, therapies designed to restore the brain’s ability to form and strengthen neural connections in regions critical to mood regulation. This is a fundamentally different approach from conventional antidepressants, which primarily target neurotransmitter levels. The distinction matters because treatment-resistant depression, by definition, persists after multiple conventional treatments have failed. Millions of Americans live with it, and the clinical need for a genuinely new mechanism of action is substantial.

The lead asset, BPL-003, is a synthetic form of 5-MeO-DMT delivered as a nasal spray. In a Phase 2b study, the compound demonstrated rapid and durable reductions in depressive symptoms following a single in-clinic visit lasting approximately two hours on average, with beneficial effects persisting for months. The FDA has granted BPL-003 Breakthrough Therapy Designation and Phase 3 activities are already underway.

The second program, VLS-01, is a buccal film formulation of DMT currently advancing in a Phase 2b study for treatment-resistant depression. A third asset, EMP-01, is an R-MDMA compound in Phase 2 development for social anxiety disorder. Together, the pipeline represents one of the most clinically advanced portfolios in the emerging psychedelic-derived therapeutics space.

The Bigger Picture for Neuroscience M&A

Lilly’s move into mental health through the AtaiBeckley acquisition reflects a growing recognition across the pharmaceutical industry that neuroscience, and specifically psychiatry, represents one of the largest underserved therapeutic markets remaining. The company framed the deal explicitly as an expansion of its neuroscience pipeline to address conditions where existing treatments consistently fall short.

The deal structure itself reveals how large pharma is approaching risk in this space. The $2.8 billion upfront payment secures the pipeline and the Phase 3 asset immediately. The $1.0 billion in CVRs ties additional payments to clearly defined regulatory and development milestones, aligning incentives between buyer and seller while limiting downside if programs do not advance as planned.

What It Signals for Small Cap Biotech

For investors tracking clinical-stage neuroscience and CNS-focused companies in the small and microcap space, the Lilly-AtaiBeckley transaction sends a direct signal. Large pharma is now willing to pay nearly $4 billion for a pre-revenue mental health company with Breakthrough Therapy Designation and Phase 3 readiness. That valuation framework applies to other companies advancing differentiated CNS programs through mid-to-late-stage development, including names like NeuroSense Therapeutics, both of which are developing therapies targeting neurological and psychiatric conditions with significant unmet need.

The biotech M&A wave that began with GSK-Nuvalent and AbbVie-Apogee earlier this year has now expanded beyond oncology into neuroscience. The message from large pharma is consistent: validated clinical data, Breakthrough Therapy Designation, and clear regulatory paths in large patient populations are commanding premium valuations regardless of therapeutic area. The pipeline of small cap companies fitting that profile remains deep.

The GEO Group (GEO) – New Contract with ICE; Raising Price Target

Posted on July 16, 2026July 16, 2026 by [email protected]

Thursday, July 16, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Contract. The GEO Group has entered into a five-year support services contract with U.S. Immigration and Customs Enforcement (“ICE”) for the activation of a federal immigration processing center at the 1,188-bed Big Horn Facility. GEO has entered into a lease agreement with the Facility owner. We view the new award positively and expect to see more such announcements going forward as ICE continues to seek out partners to assist the Agency in fulfilling its mission.

Details. The support services contract is expected to generate approximately $85 million in annual revenues in the first full year of operations, excluding transportation revenue. GEO’s support services are expected to include the exclusive use of the facility by ICE, along with security, maintenance, and food services, as well as access to recreational amenities, medical care, and legal counsel.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

T3 Defense (DFNS) – Reverse Split

Posted on July 16, 2026July 16, 2026 by [email protected]

Thursday, July 16, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Reverse Split. T3 is implementing a 50-for-1 reverse stock split. The reverse stock split will become effective as of 12:01 a.m., Eastern Time, on July 20, 2026, and the Company’s common stock will begin trading on the Nasdaq Global Market on a split-adjusted basis when the market opens on July 20, 2026.

Rationale. The Company is implementing the reverse stock split to raise the per-share bid price of the Company’s common stock above $1.00 per share and bring the Company back into compliance with Nasdaq Listing Rule 5550(a). The Company will have regained compliance once the Company’s shares trade at or above $1.00 for a minimum of 10 consecutive trading days, at which time Nasdaq will provide the Company with notice that it has regained compliance.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Power Metallic Mines Inc. (PNPNF) – Advancing the Nisk Project Toward Development

Posted on July 16, 2026July 16, 2026 by [email protected]

Thursday, July 16, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Building Momentum. Power Metallic is advancing the Nisk Project from exploration toward development, with a maiden NI 43-101 mineral resource estimate expected by the end of July 2026, followed by a Preliminary Economic Assessment which we anticipate could be completed in December 2026. The addition of mining executive Mr. Christopher Beal as Vice President of Operations further strengthens the company’s technical and operational capabilities as it progresses toward engineering studies and future development.

Drilling Continues to Deliver. Recent drilling reinforced the exceptional quality of the Lion Zone, highlighted by an intercept of 36.42 meters grading 2.83% copper equivalent, including 6.0 meters grading 12.38% copper equivalent. Combined with consistently high-grade drill results, strong metallurgical recoveries, and multiple target areas, the Nisk Project has the potential to become a significant polymetallic mining district.

Get the Full Report

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

CoreCivic, Inc. (CXW) – Redeeming 4.75% Notes

Posted on July 16, 2026July 16, 2026 by [email protected]

Thursday, July 16, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Redemption. CoreCivic has elected to redeem in full the 4.75% Senior Notes due 2027 that remain outstanding on August 12, 2026. This was an expected use of funds from the recently announced sale of two facilities to the Federal government. As of July 13, 2026, the principal amount of the outstanding 2027 Notes was $238,468,000. We anticipate additional debt reduction with a portion of the remaining sale proceeds.

Detail. The 2027 Notes will be redeemed at a redemption price equal to 100.000% of the principal amount of the then-outstanding 2027 Notes, plus the applicable “make-whole” premium specified in the indenture, as supplemented, governing the 2027 Senior Notes, plus accrued and unpaid interest to, but not including, the Redemption Date. We estimate the annual interest expense savings to be approximately $11.3 million.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Century Lithium Corp. (CYDVF) – Century Lithium Advances Commercial Readiness

Posted on July 16, 2026 by [email protected]

Thursday, July 16, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Angel Island Lithium Carbonate to High-Purity Lithium Metal. Century Lithium announced that lithium carbonate produced from its wholly owned Angel Island Lithium Project in Nevada was successfully converted into high-purity lithium metal by Alpha-En Corporation using its proprietary extraction and electrodeposition technology and subsequently incorporated into cylindrical battery cells manufactured by EaglePicher Technologies. The work was completed under the U.S. Army Small Business Innovation Research (SBIR) program, which supports the development of technologies critical to national defense.

Strong Battery Performance. Testing demonstrated that the lithium metal anodes met EaglePicher’s performance specifications and delivered higher operating voltages and improved power performance compared with control cells. These results highlight the suitability of Angel Island lithium for advanced, high-energy battery applications while validating the project’s potential to supply a domestic source of battery-grade lithium for defense-related technologies.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

The Strait of Hormuz Recovery Just Collapsed. Oil Flows Are Back Near Wartime Lows

Posted on July 15, 2026July 15, 2026 by [email protected]

The brief window of optimism that followed the US-Iran ceasefire is closing fast. Oil shipments through the Strait of Hormuz, which had recovered to roughly 50% of pre-war levels under the June 17 memorandum of understanding, have fallen sharply over the past week as the ceasefire arrangement fell apart and active fighting resumed between US and Iranian military forces. According to Goldman Sachs, flows through the strait have dropped back to an estimated 3 to 5 million barrels per day, down from approximately 10 million barrels per day in early July.

The reversal leaves the global oil market short roughly 13.4 million barrels per day of Gulf supply, a deficit that is already showing up at the pump and in the price of crude. Brent crude has jumped more than 8% over the past five trading sessions to trade back above $84 per barrel. WTI has climbed more than 8% to above $79. Both benchmarks are moving in the wrong direction for an economy that had only just begun pricing in a post-war energy recovery.

What Went Wrong

The MOU signed June 17 was supposed to reopen the strait to pre-war commercial traffic within 30 days and establish a framework for broader negotiations. For roughly four weeks, that framework held. Tanker crossings increased, oil prices declined sharply, and the global economy began adjusting to a lower energy cost environment. Gas prices fell below $4 nationally for the first time in months.

That progress has now reversed. US Central Command announced a new wave of strikes against Iranian military targets Wednesday, the fifth consecutive day of US military action in the region. Iran has continued retaliating with attacks against US installations throughout the Gulf. A second US naval blockade of the strait, which began Tuesday evening, has already redirected commercial vessels attempting to transit the waterway. Energy market analysts at Rystad Energy have stated that expectations for near-term flow normalization have failed to materialize, and the latest escalation has further reduced the probability of a recovery in the weeks ahead.

The Small Cap Squeeze Returns

For investors in the sub-$2 billion market cap space, this reversal hits on two fronts simultaneously. The consumer-facing small caps that had only just begun to benefit from lower fuel costs are now watching that relief evaporate. Companies in transportation, logistics, food service, and retail, including names like ONE Group Hospitality and Travelzoo, are right back in the margin compression environment that characterized the spring. Diesel prices, which had been trending lower, are poised to reverse alongside crude if the strait remains effectively closed.

On the other side of the trade, domestic energy producers are seeing the price environment strengthen again. Independent oil and gas operators, including names like InPlay Oil and Alliance Resource Partners, along with midstream players like Summit Midstream Partners, benefit directly from sustained crude prices above $80. The economics for US producers improve at every dollar WTI moves higher, and the re-escalation removes the near-term risk that a permanent peace deal would collapse prices back toward pre-war levels.

Goldman Sachs strategists have cautioned that recovery this time could be slower than the initial post-ceasefire rebound, given depleted global inventories and continued shipper reluctance to route through the region even via Omani waters. China, the world’s largest crude importer, had reduced its intake by 5 million barrels per day during the first phase of the conflict, but that restraint could shift as Gulf producers adjust pricing and Beijing reassesses its long-term stockpile strategy.

The ceasefire was supposed to be the beginning of the end. Instead, the strait is closing again, and the energy cost pressure that defined the first half of 2026 is threatening to define the second half as well.

Biotech IPOs Doubled in the First Half of 2026. The Funding Window for Small Cap Drug Developers Has Not Been This Wide in Years

Posted on July 15, 2026July 15, 2026 by [email protected]

The biotech sector spent the better part of three years locked out of the public markets. That era appears to be decisively over. Eighteen biotech companies completed initial public offerings in the first half of 2026, exactly double the eight that went public during the same period in 2025, according to data from BioSpace. Two of those listings, Kailera Therapeutics at $625 million and Parabilis Medicines at $670 million, shattered the previous record for the largest biotech IPO ever, a title Moderna had held since 2018.

The numbers are not just higher in volume. They are higher in conviction. The median biotech IPO in 2026 raised approximately $287.5 million, more than double the equivalent figure from early 2025 and the highest quarterly median since the pandemic-era peak of 2021. Eleven of the thirteen venture-backed biotechs that priced offerings in the first half secured at least $250 million. Investors are writing larger checks for fewer companies, and the companies receiving that capital are performing after they get to Wall Street. Most of the 2026 class is currently trading at or above its debut price.

Why the Window Opened

Two forces converged to create this environment, and they are reinforcing each other. The first is a surge in mergers and acquisitions. In Q1 2026 alone, the biopharma sector recorded 19 exits valued at $13.3 billion, the highest exit value since the fourth quarter of 2021. Deals like GSK’s $10.6 billion acquisition of Nuvalent and AbbVie’s $10.9 billion purchase of Apogee Therapeutics have demonstrated that large pharma will pay significant premiums for clinical-stage assets in high-priority therapeutic areas. That M&A activity is directly fueling IPO appetite because the companies going public increasingly resemble the exact profiles that large pharma is hunting.

The second force is a return to regulatory predictability at the FDA. The agency has moved toward greater use of advisory committees and is re-evaluating applications that previously received complete response letters, creating a more navigable path for companies with mid-to-late-stage clinical programs. The combination of active acquirers and a more transparent regulatory environment has restored investor confidence in the sector’s ability to generate returns.

What It Means for Existing Small Cap Biotechs

The implications extend well beyond the companies actually going public. A healthy IPO market lifts the entire clinical-stage biotech ecosystem. When newly public companies trade well, it signals to institutional investors that the sector is functioning again, which draws capital back into the broader small cap biotech universe, including the hundreds of companies already listed and advancing their own programs.

The therapeutic areas attracting the most capital align closely with where patent cliffs are creating the most urgency for large pharma acquirers. Oncology remains a dominant focus, with companies like Cardiff Oncology, MAIA Biotechnology, and Greenwich LifeSciences all advancing clinical programs in areas where large pharma has demonstrated a clear willingness to pay for innovation. Cardiovascular disease emerged as a significant theme in H1, with Kardigan’s $400 million offering anchored around late-stage cardiac assets. Immunology, neuroscience, and rare disease continue to draw investor interest as well, with companies like Eledon Pharmaceuticals developing differentiated programs in therapeutic areas where unmet need and commercial opportunity intersect.

The second half is expected to accelerate further. Nasdaq has estimated that a dozen additional biotech IPOs could price in Q3 alone, and companies like Scribe Therapeutics, co-founded by CRISPR pioneer Jennifer Doudna, are already in the filing process. The biotech funding window has not been this open since 2021. The difference this time is that the market is rewarding discipline, clinical data, and clear regulatory paths rather than early-stage platforms and promises. That distinction is what makes this cycle more durable than the last one.

June’s Cool CPI Print Sends Treasuries Rallying and Fed Hike Odds Tumbling

Posted on July 14, 2026July 14, 2026 by [email protected]

Consumer prices came in far cooler than expected in June, and markets reacted fast. Treasury yields dropped sharply and bets on a July interest rate hike nearly evaporated.

The Consumer Price Index fell 0.4% from May to June, the largest single-month decline since April 2020. On an annual basis, inflation eased to 3.5%. Both figures beat expectations by a wide margin, with forecasts calling for just a 0.1% monthly decline and a 3.8% annual reading.

Falling energy prices did much of the work, as drivers saw real relief at the pump. That’s a sharp reversal from May, when a temporary spike in gas prices tied to conflict in the Middle East had pushed inflation higher.

Core inflation, which strips out volatile food and energy prices, also came in soft. Core prices were flat month-over-month and up 2.6% year-over-year, again below expectations that had priced in a 0.2% monthly gain driven by higher travel and electronics costs.

Bond traders repriced their outlook almost immediately. The two-year Treasury yield, the maturity most sensitive to near-term Fed policy, fell as much as 14 basis points to 4.14%, on pace for its biggest one-day drop since February. Rate-hike expectations for the July Fed meeting, as measured by the swaps market, collapsed from around 40% probability before the report to roughly 20% after.

Market watchers are describing the report as a broad, downside surprise. Fear of a hot print had been building heading into the release, so the miss is being read as bond-friendly and likely to help steepen the yield curve. The growing consensus is that the Fed holds steady rather than moves on rates this month.

The timing is notable. The report landed just a day before the Fed chair is set to testify before Congress for the first time in his role, with inflation expected to be a central topic. Prepared remarks released ahead of the hearing struck a hawkish tone, emphasizing zero tolerance for persistently high inflation. It’ll be worth watching whether that tone shifts now that the data has moved in the Fed’s favor.

The CPI release also landed alongside a strong batch of bank earnings, with results pointing to a resilient underlying economy even as price pressures ease. That combination matters: a slowdown in inflation paired with weak growth would raise questions about the economy’s health, but paired with solid earnings, it reads instead as a sign that price pressures are normalizing without derailing activity.

It’s also a meaningful shift in narrative after a rough spring. May’s inflation report ran hot, largely because of an energy price spike tied to geopolitical tension, and it left markets bracing for a similarly uncomfortable June number. Instead, energy prices reversed course and gave consumers breathing room, which shows up clearly in both the headline and core figures.

For everyday spending, this kind of pullback tends to show up first at the pump and then gradually filters into other categories, though the core reading suggests broader price pressures outside food and energy are still holding fairly steady rather than reversing outright.

Put together, cooler inflation paired with solid earnings is often the combination markets like best — it eases pressure on the Fed without signaling economic weakness. With rate-hike odds falling and yields pulling back, the setup looks constructive for both bonds and rate-sensitive stocks heading into this week’s testimony and the rest of earnings season. Investors will likely be watching upcoming data closely to see whether June’s cooldown holds or proves to be a one-month blip.

NanoViricides (NNVC) – NanoViricides Announces Phase 2 Ebola Trial Approval and Prepares Next Regulatory Filing

Posted on July 14, 2026July 14, 2026 by [email protected]

Tuesday, July 14, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 2 Ebola Trial Advancing As Expected. Nanoviricides announced that it has received approval from the National Ethics Committee in the Democratic Republic of Congo (DRC) for its Phase 2 clinical trial of NV-387 in Ebola. The next step is the filing of a Clinical Trial Application with ACOREP, the DRC regulatory authority. This meets one of our expected milestones to start of patient treatment during summer 2026.

Two Phase 2 Trials Should Begin In A Matter of Weeks. The approval by the National Ethics Committee was a step in the process of starting clinical trials in the DRC. The company has shipped the clinical supplies of NV-387 and is preparing for a Phase 2 trial in MPox and a separate Phase 2 trial in Ebola. We expect regulatory approvals in the next several weeks to allow both trials to begin treating patients during summer 2026 through fall 2026.

Get the Full Report

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

First Phosphate Corp. (FRSPF) – Final Tranche of Private Placement Financing Closed

Posted on July 14, 2026July 14, 2026 by [email protected]

Tuesday, July 14, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Private Placement Financing. First Phosphate completed the final tranche of its non-brokered private placement with the issuance of 960,500 flow-through shares and 178,325 hard dollar units. Across both tranches, the company raised total gross proceeds of C$17,698,290 with the issuance of 7,238,070 flow-through shares and 1,611,075 hard dollar units. The hard dollar units were priced at C$2.00 per unit and included one common share and one warrant exercisable at C$2.50 per share through December 31, 2026, subject to accelerated expiry. The flow-through shares were issued at C$2.00 per share.

Board Appointment. First Phosphate appointed Mr. Peter Kent to its board of directors, effective July 10, expanding the board to five members from four. Mr. Kent, who previously served as President, director, and advisor to the company, replaces Mr. John Passalacqua, CEO and director, on the Audit Committee. A former Canadian Minister of the Environment and Minister of State for the Americas, Mr. Kent brings extensive experience in environmental assessment, resource development policy, and regulatory affairs.

Get the Full Report

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Cadrenal Therapeutics (CVKD) – CAD-1005 Phase 2 Trial Data In HIT Presented at ISTH Meeting

Posted on July 14, 2026July 14, 2026 by [email protected]

Tuesday, July 14, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

CAD-1005 Phase 2 Study Reported At Medical Meeting. Cadrenal presented data from its Phase 2 trial testing CAD-1005 in HIT (Heparin Induced Thrombocytopenia) at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress. As discussed in our Research Note on February 25, the trial did not meet its Primary Endpoint, but successfully characterized CAD-1005 and had unanticipated findings that were better than expected.

CAD-1005 Reduced Thrombotic Events Without Platelet Recovery. The Phase 2 placebo-controlled trial was designed to test CAD-1005 with standard anticoagulant therapy. Its Primary Endpoint was an improvement in platelet recovery, a biomarker for predicting thrombotic events and outcome. This primary endpoint did not meet statistical significance, although the secondary endpoint of reduction in thrombotic events showed a clinically meaningful improvement.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Alliance Resource Partners (ARLP) – Updating Estimates Ahead of ARLP’s Earnings Report

Posted on July 14, 2026July 14, 2026 by [email protected]

Tuesday, July 14, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Updating Estimates. We have increased our 2Q 2026 revenue, EBITDA, and EPU estimates to $553.5 million, $181.2 million, and $0.62, respectively, from $521.6 million, $164.8 million, and $0.54. We increased our 2Q coal sales estimate to 8.7 million tons from 8.3 million tons as we have recalibrated the cadence of sales for the remaining quarters of 2026 while keeping annual coal sales at 35.0 million tons. Other adjustments include modestly higher coal pricing and a recalibration in the quarterly cadence of Other Revenue. We have increased our FY 2026 revenue, EBITDA, and EPU estimates to $2.209 billion, $723.7 million, and $2.22, respectively, from $2.198 billion, $714.7 million, and $2.20.

AllDale Minerals Acquisition. Alliance Resource Partners (ARLP) recently completed its previously announced acquisition of the remaining ownership interests in AllDale Minerals III and IV for approximately $206.2 million, strengthening its Oil & Gas Royalties business. The transaction was funded through a combination of cash on hand, borrowings under the company’s revolving credit facility, and a new $150 million term loan maturing in January 2028.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).